Logo

IMV Reports the First Patient Dosing in the P-IIb (VITALIZE) Study for MVP-S + Keytruda (pembrolizumab) for the Treatment of R/R DLBCL

Share this

IMV Reports the First Patient Dosing in the P-IIb (VITALIZE) Study for MVP-S + Keytruda (pembrolizumab) for the Treatment of R/R DLBCL

Shots:

  • The first patient has been dosed in the P-IIb (VITALIZE) trial to evaluate the clinical benefit of IMV’s MVP-S + Merck’s Keytruda with/out CPA in ~150 patients with r/r DLBCL who have received 2 prior lines of systemic therapy & ineligible or failed ASCT or CAR-T therapy. The results are expected in summer 2022
  • The 1EPs is ORR and measured by the number of patients achieving the best response of PR & CR @2yr. treatment period while exploratory EPs include cell-mediated immune response, tumor immune cell infiltration, and biomarker analysis
  • Additionally, the results from the (SPiReL) study showed that MVP-S + Keytruda induced DCR, grade 1 or 2 AEs & showed 75% ORR in PD-L1+ patients

Ref: IMV | Image: IMV

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions